Genmab 1 article

The protein-therapeutics profile of Genmab is anchored in antibody therapeutics, with DuoBody bispecific antibody platform adding the receptor, cytokine or multispecific design context that distinguishes its platform. The company links HexaBody antibody engineering platform with bispecific T-cell engaging antibodies; Fc-mediated antibody effector enhancement shows how antibody format or binding architecture is translated into a biological effect. For Genmab, individual protein products remain separate tags, while solid tumor antibody therapeutics adds context to the broader biologics profile.

Drug Discovery

September 23, 2026, 7:20 AM · 5 mins read

B cell non Hodgkin lymphoma pipeline grows as new trials target aggressive disease

A wave of clinical trials and new drugs is changing the B cell non Hodgkin lymphoma treatment field. More than seventy five companies are now moving over eighty therapies through the pipeline.